SEARCH

SEARCH BY CITATION

References

  • 1
    Johnson PJ. The equine metabolic syndrome – peripheral Cushing’s syndrome. Vet Clin North Am Equine Pract 2002; 18: 271293.
  • 2
    Schott HC. Pituitary pars intermedia dysfunction: equine Cushing’s disease. Vet Clin North Am Equine Pract 2002; 18: 237270.
  • 3
    McFarlane D, Donaldson MT, Saleh TM, Cribb AE. The Role of Dopaminergic Neurodegeneration in Equine Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease). New Orleans, LA: Forty-ninth Annual Convention of the American Assocication of Equine Practitioners. http://www.ivis.org/proceedings/AAEP/2003/macfarlane/ivis.pdf, 2003.
  • 4
    Hood DM. Laminitis as a systemic disease. Vet Clin North Am Equine Pract 1999; 15: 481494.
  • 5
    Bailey SR, Marr CM, Elliott J. Current research and theories on the pathogenesis of acute laminitis in the horse. Vet J 2004; 167: 129142.
  • 6
    Donaldson MT, LaMonte BH, Morresey P, Smith GJB. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing’s disease). J Vet Intern Med 2002; 16: 742746.
  • 7
    Perkins GA, Lamb S, Erb HN, Schanbacher B, Nydam DV, Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing’s disease wih cyproheptadine or pergolide. Equine Vet J 2002; 34: 679685.
  • 8
    Orth DN, Holscher MA, Wilson MG, Nicholson WE, Plue RE, Mount CD. Equine Cushing’s disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 1982; 110: 14301441.
  • 9
    Elliott J, Berhane Y, Bailey SR. Effects of monoamines formed in the cecum of horses on equine digital blood vessels and platelets. Am J Vet Res 2003; 64: 11241131.
  • 10
    Goudreau JL, Manzanares J, Lookingland KJ, Moore KE. 5HT2 receptors mediate the effects of stress on the activity of periventricular hypophyseal dopaminergic neurons and the secretion of alpha-melanocyte-stimulating hormone. J Pharmacol Exp Ther 1993; 265: 303307.
  • 11
    McGowan CM, Neiger R. Efficacy of trilostane for the treatment of equine Cushing’s syndrome. Equine Vet J 2003; 35: 414418.
  • 12
    Lincoln GA, Almeida OF, Klandorf H, Cunningham RA. Hourly fluctuations in the blood levels of melatonin, prolactin, lutenizing hormone, follicle stimulating hormone, testosterone, tri-iodothyronine, thyroxine and cortisol in rams under artificial photoperiods, and the effects of cranial sympathectomy. J Endocrinol 1982; 92: 237250.
  • 13
    Tortonese DJ. Interaction between hypothalamic dopaminergic and opioidergic systems in the photoperiodic regulation of pulsatile luteinizing hormone secretion in sheep. Endocrinology 1999; 140: 750757.
  • 14
    McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin-releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006; 30: 276288.
  • 15
    Dilman VM, Revskoy SY, Golubev AD. Neuroendocrine-ontogenetic mechanism of aging: toward an integrated theory of aging. Int Rev Neurobiol 1986; 28: 89156.
  • 16
    Dilman VM, Yound JK. Development, Aging and Disease – A New Rationale for an Intervention Strategy. Chur: Harwood Academic Publishers, 1994.
  • 17
    Couetil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996; 10: 16.
  • 18
    Knottenbelt DC. Saunders Equine Formulary. Liverpool: Saunders Elsevier, 2006.
  • 19
    Guerin MV, Deed JR, Kennaway DJ, Matthews CD. Plasma melatonin in the horse: measurements in natural photoperiod and in acutely extended darkness throughout the year. J Pineal Res 1995; 19: 715.
  • 20
    Guillaume D, Rio N, Toutain PL. Kinetic studies and production rate of melatonin in pony mares. Am J Physiol 1995; 268: R1236R1241.
  • 21
    Diekman MA, Braun W, Peter D, Cook D. Seasonal serum concetrations of melatonin in cycling and non-cycling mares. J Anim Sci 2002; 80: 29492952.
  • 22
    Bailey SR, Katz LM, Berhane Y, Samuels T, De Brauvere N, Marr CM, Elliott J. Seasonal changes in plasma concentrations of cecum-derived amines in clinically normal ponies and ponies predisposed to laminitis. Am J Vet Res 2003; 64: 11321138.
  • 23
    Piccione G, Assenza A, Fazio F, Percipalle M, Caola G. Central fatigue and nycthemeral change of serum tryptophan and serotonin in the athletic horse. J Circadian Rhythms 2005; 3: 69.
  • 24
    Bailey SR, Elliott J. Plasma 5-hydroxytryptamine constricts equine digital blood vessels in vitro: implications for pathogenesis of acute laminitis. Equine Vet J 1998; 30: 124130.
  • 25
    Millington WR, Dybdal NO, Dawson R, Manzini C, Mueller GP. Equine Cushing’s disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary. Endocrinology 1988; 123: 15981604.
  • 26
    McFarlane D, Dybdal NO, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005; 17: 7380.
  • 27
    Johnson AL, Malinowski K. Daily rhythm of cortisol, and evidence for a photo-inducible phase for prolactin secretion in nonpregnant mares housed under non-interrupted and skeleton photoperiods. J Anim Sci 1986; 63: 169175.
  • 28
    Irvine CHG, Alexander SL. Factors affecting the circadian rhythm in plasma cortisol concentrations in the horse. Domest Anim Endocrinol 1994; 11: 227238.
  • 29
    Black A, Schoknecht PA, Ralston SL, Shapses SA. Diurnal variation and age differences in the biochemical markers of bone turnover in horses. J Anim Sci 1999; 77: 7583.